Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs aflibercept for macular edema secondary to central or hemiretinal vein occlusion
2020-000441-13Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab in central retinal vein occlusion with macular edema, macular edema and Vein occlusion (RVO) (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in BCVA at Week 24. Started Jul 2020; status: completed.
02
Drugs
faricimab
03
Conditions
central retinal vein occlusion with macular edemamacular edemaVein occlusion (RVO)
Beyond the preview
Go deeper on 2020-000441-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000441-13.